MicroCME: The Work-Up of CSU and Using Biomarkers to Predict Outcomes and Future Therapies
![]()
Price: FREE to members; $20 non-members
Length: 25 minutes
This microlearning, presented by Dr. David Khan, discusses the work-up of CSU and how to use biomarkers to predict outcomes and future therapy options.
Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Primary Care Providers
Fellows-in-Training
Learning Objectives
By participating in this course, learners should be able to:
- Apply evidence-based strategies for the diagnostic work-up of CSU, interpret the relevance of biomarkers in predicting disease outcomes, and incorporate these insights into the selection of current and emerging therapies.
- Identify and evaluate emerging treatments for CSU, understand their mechanisms of action, and incorporate these advancements into clinical practice to enhance patient care.
Planners and Reviewers
Brianne Nicole Navetta-Modrov, MD, FACAAI
Nothing to Disclose
Deepa Patadia, MD
Nothing to Disclose
Deepti Vellaichamy Manian, MD
Nothing to Disclose
Farah Nawaz Khan, MD, FACAAI
Doximity: stocks/stock options
Joel S. Klein, MD, FACAAI
Nothing to Disclose
Karen M. Anstey, MD
Nothing to Disclose
Tammy Peng, MD
Nothing to Disclose
Mary Brandt Hudelson, MD, FACAAI
Nothing to Disclose
Mechelle Miller Vazquez, MD
Nothing to Disclose
Available Credit
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Attendance
- 0.50 CBRN

Facebook
X
LinkedIn
Forward